Brief: Editas Medicine Announces New Edit-301 Safety And Efficacy Data In 17 Patients

Editas Medicine

11/12/2023 17:03

Dec 11 (Reuters) - Editas Medicine Inc  EDIT.O :
    * EDITAS MEDICINE ANNOUNCES NEW EDIT-301 SAFETY AND EFFICACY
DATA
IN 17 PATIENTS, PRESENTED TODAY AT THE AMERICAN SOCIETY OF
HEMATOLOGY (ASH) ANNUAL MEETING AND IN A COMPANY-SPONSORED
WEBINAR
    * EDITAS MEDICINE INC - ALL RUBY PATIENTS WITH ≥5 MONTHS
FOLLOW-UP
HAVE ACHIEVED A NORMAL HEMOGLOBIN LEVEL AND A FETAL HEMOGLOBIN
LEVEL OF >40%
    * EDITAS MEDICINE INC - ALL PATIENTS TREATED IN RUBY TRIAL
ARE
FREE OF VASO-OCCLUSIVE EVENTS POST-EDIT-301 INFUSION
    * EDITAS MEDICINE INC: EDIT-301 WAS WELL-TOLERATED
    * EDITAS MEDICINE:EDIT-301 SHOWED SAFETY PROFILE CONSISTENT
WITH
MYELOABLATIVE CONDITIONING WITH BUSULFAN,AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANT

Source text for Eikon:  ID:nGNX2946Mz 
Further company coverage:  EDIT.O 

 ((Reuters.Briefs@thomsonreuters.com;))